Claims for Patent: 7,732,430

Summary for Patent: 7,732,430

Title:	Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Abstract:	A method of contraception in mammalian females, which method comprises the oral administration of an estrogenic component and a progestogenic component to a female of childbearing capability in an amount effective to inhibit ovulation, wherein the estrogenic component is selected from the group consisting of substances represented by the following formula (1) ##STR00001## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R.sub.5, R.sub.6, R.sub.7 is a hydroxyl group; and no more than 3 of R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and/or a progestogenic component.
Inventor(s):	Bunschoten; Evert Johannes (Heesch, NL), Coelingh Bennink; Herman Jan Tijmen (Driebergen, NL), Holinka; Christian Franz (New York, NY)
Assignee:	Pantarhei Bioscience B.V. (Zeist, NL)
Application Number:	10/478,365
Patent Claims:	1. A contraceptive method, comprising administering orally an estrogenic component and a progestogenic component to a mammalian female of childbearing capability in an effective amount to inhibit ovulation, said estrogenic component being selected from the group consisting of substances represented by the following formula: ##STR00002## in which formula R.sub.1, R.sub.2, R.sub.3, R.sub.4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R.sub.5, R.sub.6, R.sub.7 is a hydroxyl group; and no more than 3 of R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method, which precursors are derivatives of the aforementioned estrogenic substances wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; and mixtures of one or more of the aforementioned substances or precursors, wherein the method does not employ co-administration of an LHRH composition. 2. The method according to claim 1, wherein the progestogenic component is administered in an amount which is equivalent to a daily oral dosage of 0.3 to 20 .mu.g levonorgestrel per kg of bodyweight. 3. A pharmaceutical kit comprising at least 20 oral dosage units, wherein at least 10 units contain between 0.01 and 20 mg of an estrogenic component and at least 10 units contain a progestogenic component in an amount equivalent to 30-750 .mu.g levonorgestrel, said estrogenic component being selected from the group consisting of substances represented by the following formula: ##STR00003## in which formula R.sub.1, R.sub.2, R.sub.3, R.sub.4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R.sub.5, R.sub.6, R.sub.7 is a hydroxyl group; and no more than 3 of R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method, which precursors are derivatives of the aforementioned estrogenic substances wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue; and mixtures of one or more of the aforementioned substances or precursors, wherein the oral dosage units do not contain an LHRH composition. 4. The pharmaceutical kit according to claim 3, comprising at least 10 oral dosage units that contain between 0.01 and 20 mg of the estrogenic component and contain the progestogenic component in an amount equivalent to 30-750 .mu.g levonorgestrel. 5. The pharmaceutical kit according to claim 4, comprising at least 20 oral dosage units containing the combination of the estrogenic component and the progestogenic component. 6. The pharmaceutical kit according to claim 4, comprising from 20-35 oral dosage units, wherein 10-35 units contain the combination of the estrogenic component and the progestogenic component in the indicated amounts, 0-25 units contain no progestogenic component and the estrogenic component in the indicated amounts, and 0-8 units contain no estrogenic component and no progestogenic component. 7. The pharmaceutical kit according to claim 4, wherein the kit comprises at least 28 oral dosage units and all the included dosage units contain the combination of the estrogenic component and the progestogenic component. 8. The pharmaceutical kit according to claim 3, wherein the kit comprises at least 3 oral dosage units that contain no estrogenic component and no progestogenic component. 9. The pharmaceutical kit according to claim 4, wherein 10-32 oral dosage units contain the combination of the estrogenic component and the progestogenic component, and 3-18 units contain the estrogenic component and no progestogenic component. 10. The pharmaceutical kit according to claim 9, wherein 10-20 oral dosage units contain the combination of the estrogenic component and the progestogenic component, 10-18 units contain the estrogenic component and no progestogenic component, and at most 1 unit contains no estrogenic component and no progestogenic component. 11. The method according to claim 1, wherein the administration of the estrogenic component and the progestogenic component is in an amount effective to inhibit ovulation during a period of at least 20 days. 12. The method according to claim 1, wherein R.sub.3 represents a hydroxyl group or an alkoxy group. 13. The method according to claim 1, wherein 3 of the groups R.sub.1, R.sub.2, R.sub.3 and R.sub.4 represent hydrogen atoms. 14. The method according to claim 1, wherein the method comprises uninterrupted oral administration of the estrogenic component during a period of at least 10 days. 15. The method according to claim 1, wherein the method comprises uninterrupted oral administration, during a period of at least 10 days, of a combination of the estrogenic component and the progestogenic component. 16. The method according to claim 1, wherein the method comprises uninterrupted oral administration of a combination of the estrogenic component and the progestogenic component during a period of at least 20 days. 17. The method according to claim 1 further comprising, wherein the method comprises uninterrupted oral administration of a combination of the estrogenic component and the progestogenic component during a period of at least 28 days. 18. The method according to claim 15 wherein the method comprises an interval of at least 2 days, during which no progestogenic component and no estrogenic component is administered and wherein the resulting decrease in serum concentration of the progestogenic component and the estrogenic component induces menses. 19. The method according to claim 15, wherein the method comprises uninterrupted oral administration of the estrogenic component during a period of at least 28 days and wherein, following the combined administration of the estrogeriic component and the progestogenic component, the estrogenic component and no progestogenic component are administered during 3-18 consecutive days and the resulting decrease in serum concentration of the progestogenic component induces menses. 20. The method according to claim 1, wherein the method comprises at least once daily oral administration of the estrogenic component and the progestogenic component during a period of at least 10 days. 21. The method according to claim 1, wherein the estrogenic component is orally administered in an amount of less than 1 mg per kg of bodyweight per day. 22. The method according to claim 1, wherein the estrogenic component is orally administered in an amount of at least 1 .mu.g per kg of bodyweight per day.